- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Kodiak Sciences Inc.
Headquarters: Palo Alto, CA, United States
Website: http://www.kodiak.com
Year Founded: 2009
Status: Public
Industry Sector: HealthTechnology
CEO: Victor Perlroth, MD, MBA
Number Of Employees: 109
Enterprise Value: $525,473,323
PE Ratio: -1.47
Exchange/Ticker 1: NASDAQ:KOD
Exchange/Ticker 2: N/A
Latest Market Cap: $259,596,400
BioCentury | Jul 25, 2023
Product Development
July 24 Quick Takes: Kodiak sinks on tarcocimab DME miss
Plus: BMS takes stake in Immatics and updates from Syndax, Incyte, Crescendo, Bavarian Nordic, Horizon, CERSI
BioCentury | Aug 9, 2022
Politics, Policy & Law
Aug. 8 Quick Takes: Insulin cap, carried interest out, drug pricing regulation in
Plus cash crunch for Clovis, tumble for Novavax, clinical updates from CinCor, Reata, Hutchmed, Kodiak and more
BioCentury | Apr 11, 2022
Data Byte
Biotech’s negative catalyst run
A string of poor catalyst outcomes contributed to negative sentiment toward biotech in 1Q22
BioCentury | Mar 3, 2022
Management Tracks
McKinsey’s Evers joining Evotec as CBO
Plus new EVPs of legal, HR at Genmab, and updates from Seegene, Syndax, Candel, Graphite, Owkin and more
BioCentury | Feb 23, 2022
Product Development
Frosty market reception for Kodiak after bearish ophthalmic readout
Share value evaporates after disappointing AMD data for Eylea competitor, but Kodiak looks ahead to more readouts
BioCentury | Oct 21, 2021
Management Tracks
Dana-Farber’s David Livingston dies at 80
Plus: Alzheimer's Association, Aerie, Elevation, BioPorto, Opus and more
BioCentury | Nov 19, 2020
Finance
Nov. 18 Quick Takes: Venture rounds for Elevation, Pharvaris as Kodiak follow-on brings in $560M; plus AbCellera takes out Trianni for $90M and more
Elevation raises $65M series B, names Leland CEOElevation Oncology Inc. raised $65 million in a series B round and promoted founder Shawn Leland from CBO to CEO. The venture round was led by
BioCentury | Jun 24, 2020
Finance
AsclepiX aims for basket of retinal indications with $35M series A
Perceptive Xontogeny Venture Fund invested alongside Perceptive Advisors’ master life sciences fund
BioCentury | Jan 4, 2020
Finance
All’s well that ends well
Biotechs across all market cap tiers gained in 4Q19, recovering from 3Q losses
Items per page:
1 - 10 of 26